Sonic Healthcare Limited (ASX:SHL): Diagnostics Revenue and Profit Growth Mark FY26 Results

Aditi Sarkar

30 October 2026 08:16 PM AEDT

Sonic Healthcare Limited (ASX:SHL): Diagnostics Revenue and Profit Growth Mark FY26 Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue reached A$10,867 million, up 13% YoY.
Underlying EBITDA was A$1,933 million, increasing 11% YoY.
Underlying net profit reached A$621 million, up 17% YoY.
Statutory net profit was A$608 million, an increase of 18% YoY.

Sonic Healthcare Limited provides medical diagnostic services, including pathology and laboratory medicine, across its international operations. Sonic Healthcare Limited (ASX:SHL) reported revenue and earnings growth in FY26, with the result reflecting service activity, operating leverage and business integration during the year.

Revenue and reported earnings

Sonic Healthcare Limited (ASX:SHL) reported FY26 revenue of A$10,867 million, an increase of 13% YoY. The group also recorded underlying EBITDA of A$1,933 million, up 11% YoY. EBITDA represents earnings before interest, tax, depreciation and amortisation; the underlying measure should be distinguished from the statutory figure presented in the same results release.

Statutory EBITDA was A$1,882 million, rising 9% YoY. Underlying net profit was A$621 million, increasing 17% YoY, while statutory net profit reached A$608 million, up 18% YoY. Reporting both statutory and underlying figures helps clarify the accounting basis used for each result rather than treating the two profit measures as identical.

Sonic Healthcare Limited (ASX:SHL) reported underlying earnings per share of A125.6 cents, increasing 14% YoY. Statutory earnings per share were A123.0 cents, up 15% YoY. Earnings per share measures profit attributable on a per-share basis and can move differently from aggregate earnings because of share-count changes and other factors.

Diagnostics operations and integration

The company provides pathology and laboratory diagnostic services to patients, clinicians and healthcare systems. Sonic Healthcare Limited (ASX:SHL) attributed its FY26 performance in part to revenue growth, operating leverage and the realisation of synergies. These terms describe different mechanisms: activity-related revenue, the relationship between revenue and operating costs, and benefits from combining business operations.

Diagnostic laboratories operate within clinical quality and accreditation frameworks, and the scale of testing activity is affected by medical demand and healthcare-provider arrangements. Sonic's international footprint also means reported group results aggregate businesses across different systems and markets. The annual revenue total should not be interpreted as a uniform growth rate in every operating location.

Sonic Healthcare Limited (ASX:SHL) stated that it achieved its FY26 underlying EBITDA guidance. This is a statement about the completed reporting period, separate from any assumptions about subsequent trading. The statutory and underlying earnings measures show the same broad direction of year-on-year change, while retaining differences in accounting treatment.

Financial interpretation and business dependencies

The company's earnings statement describes ongoing capital management and the integration of businesses across its diagnostic network. Managing laboratory operations involves staffing, equipment, technology, information systems and compliance requirements. Sonic Healthcare Limited (ASX:SHL) therefore reports through a business model where service quality and operating efficiency are relevant alongside total revenue.

Revenue expansion can reflect multiple effects, including changes in service activity, acquisitions and other commercial factors. However, the FY26 headline figures alone do not establish the contribution of every driver. It is more accurate to separate management's stated performance factors from any unsupported explanation of market share or pricing trends.

The difference between A$1,933 million of underlying EBITDA and A$1,882 million of statutory EBITDA also illustrates why a publication should identify the measure alongside each amount. Neither is interchangeable with net profit, which reflects additional expense categories and applicable tax effects.

The figures were released on 20 August 2026 for the financial year ended 30 June 2026. The reporting period therefore precedes the dated share price in the introductory paragraph; the share price is not itself a measure of FY26 diagnostic service revenue or profitability.

Key Insights

Sonic Healthcare Limited (ASX:SHL) reported FY26 increases in revenue, underlying EBITDA and statutory profit. The results reflect the financial performance of its diagnostics network and the influence of operating leverage and integration on the reported earnings.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.